The objective of the study was to compare the impact of oral and i.v. ganciclovir on resource use and direct health care costs, from the perspective of the UK National Health Service (NHS).
The analytical framework used was cost analysis.
The sources of data were an open, randomized clinical trial, and additional research which collected resource use and cost data.
From the perspective of the UK NHS, the expected cost of i.v. ganciclovir for initial induction and 140 days maintenance and reinduction therapy was £730 higher than that of oral (£8145 vs £7415).
Conservative estimates which did not favour oral ganciclovir were used wherever possible.
Overall, the resource use and costs of maintenance therapy with oral ganciclovir calculated in the model used for this study were lower than those of i.v. ganciclovir, principally reflecting lower costs for the administration of therapy.
In this model the drug cost of ganciclovir maintenance therapy was excluded.
Mots-clés Pascal : SIDA, Virose, Infection, Cytomegalovirus humain, Betaherpesvirinae, Herpesviridae, Virus, Antiviral, Rétinite, Infection opportuniste, Association, Traitement, Voie orale, Voie intraveineuse, Chimiothérapie, Etude comparative, Voie administration, Ganciclovir, Coût, Homme, Nucléoside acyclique, Purine nucléoside, Immunopathologie, Immunodéficit, Economie santé, Oeil pathologie, Rétinopathie
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Human cytomegalovirus, Betaherpesvirinae, Herpesviridae, Virus, Antiviral, Retinitis, Opportunistic infection, Association, Treatment, Oral administration, Intravenous administration, Chemotherapy, Comparative study, Route of administration, Ganciclovir, Costs, Human, Acyclic nucleoside, Purine nucleoside, Immunopathology, Immune deficiency, Health economy, Eye disease, Retinopathy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0015923
Code Inist : 002B02S05. Création : 21/05/1997.